Background: Laboratory testing for KRAS Kirsten rat sarcoma viral oncogene homolog) mutations in metastatic colorectal cancer (mCRC) is performed by various methods in China, but there is no standardized system for proficiency testing or assay performance evaluations. The aim of this study was to evaluate assay and laboratory performance with artificial samples derived from formalin-fixed, paraffin-embedded (FFPE) cell lines. Methods: Artificial FFPE samples were prepared from cultured cell lines to construct a proficiency panel of 10 samples covering eight KRAS mutations and two wildtype samples. The samples were validated by Sanger sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The panel was distributed to participating laboratories and their reported results were compared to the reference sequences. Results: The percentages of mutant KRAS alleles in each mutant sample were more than 50% by MALDI-TOF-MS. Sixty-three laboratories reported results, including 41 hospital laboratories and 22 commercial laboratories and reagent manufacturers. Only 55.6% (35/63) of the laboratories correctly identified the mutations in all samples and 33.3% (21/63) reported at least one false-positive result.
Introduction
The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene is located on human chromosome 12, it contains four coding exons and one 5′ non-coding exon, all of which encode the RAS protein. KRAS is a component of the epidermal growth factor receptor (EGFR) signaling pathway, which regulates cancer development and progression. Approximately 40% of patients with metastatic colorectal cancer (mCRC) harbor KRAS mutations that yield a constitutively active protein [1] [2] [3] and dysregulation of the mitogen-activated protein kinase (MAPK) cascade, leading to disease progression associated with a lack of response to anti-EGFR monoclonal antibodies, cetuximab, and panitumumab [4] . The most common KRAS mutations occur in codons 12 and 13, and occasionally in codon 61 [5, 6] . In 2006, Lievre first reported that KRAS mutations may lead to cetuximab resistance [7] . Since then, the mutation status of the KRAS oncogene has been developed as a predictive biomarker; determining the KRAS status in mCRC patients is now part of standard clinical practice in the USA, Europe, and Asia [8] .
Many methods for KRAS mutation detection have been developed, including Sanger sequencing, pyrosequencing, the amplification refractory mutation system (ARMS) [9] , denaturing high-performance liquid chromatography (dHPLC) [10] , and high-resolution melting real-time PCR (PCR-HRM) [11] . Each method has advantages and limitations, and there is no gold standard methodology for KRAS mutation detection [12] . Under these circumstances, external quality assessment (EQA) or proficiency testing (PT) become essential management measures to assess the proficiency and performance of various KRAS test methods and laboratories and to identify systematic errors in methodology.
One of the primary concerns in connection with EQA and PT is the sensitivity of an assay for determining the lowest mutated alleles that can be used for analysis [13] [14] [15] . For example, Sanger sequencing has a detection limit of 10%-15% mutated alleles [16] , while ARMS methods identify the mutation status to a level of only 1% mutated alleles [17] . EQA and PT samples are typically formalin-fixed, paraffin-embedded (FFPE) tissues from surgical resections or fine needle biopsies [18, 19] , which contain various proportions of mutated and wildtype cells. Discrepant results sometimes occur due to lowlevel mutations. The European Society of Pathology (ESP) assessment conducted in eight European countries [18] found that different results were reported by the scheme organizer and reference laboratory because of a very low signal for G12R, which was missed by Sanger sequencing (detection limit, 10%-15% for mutant alleles) [16] but could be detected by pyrosequencing (detection limit for mutant alleles, 5%) [20] and allele-specific PCR (detection limit for mutant alleles, 2.5%-5%) [21] . In an Italian EQA, discordant results were produced by different assays [22] . In the clinical setting, the lowest mutated alleles that can be detected by the KRAS assay should be validated to determine the minimum percent tumor requirements (assuming that all tumor cells have heterozygous mutation, the minimum percentage of tumor cells is twice the lowest percentage of mutated alleles). Based on a pathologist's determination, only samples with more than the minimum tumor percentage should be tested. Therefore, it is necessary to determine how laboratories perform assays when the percentage of tumor cells is sufficient for testing.
In order to obtain samples that satisfy these conditions, we produced artificial FFPE specimens from cultured cell lines to simulate clinical samples. Here we have described the first nationwide KRAS PT survey in China, organized by the National Center for Clinical Laboratories (NCCL), and discussed laboratory and assay performance for samples in which the percentage of tumor cells was sufficient to yield a result.
Materials and methods

Preparation of FFPE samples
FFPE samples were prepared from the KRAS mutation-positive cell lines LS 174T, SW480, NCI-H358, A549, SW1116, H157, and LOVO, which harbor the most common KRAS mutations in codons 12 and 13: G35A (G12D), G35T (G12V), G34T (G12C), G34A (G12S), G35C (G12A), G34C (G12R), and G38A (G13D). Colo205, a wild-type KRAS colorectal cancer cell line was also prepared. These cell lines were purchased from Cell Bank, Type Culture Collection, Chinese Academy of Sciences. Briefly, aliquots of 1-2 × 10 7 cells were collected and washed three times with phosphate-buffered saline to remove the medium. Then, pure mutant and wild-type tumor cells were fixed in 4% neutral buffered formalin for about 1 h at room temperature. The cell pellets were dehydrated with graded ethanol and made transparent with xylene. The cell pellets were transferred to small Eppendorf tubes containing melted liquid paraffin, incubated for 10 min, and mixed with a pipette tip before transferring the tube to ice to solidify the wax and stored at 4 °C overnight. The blocks were embedded in paraffin again the next day by using standard histotechnical apparatus. Hematoxylin-eosin (HE) staining was used to ensure the representative morphology of each tumor sample [14] , estimate the number of cells present, and assess the uniformity of cell distribution. Each sample consisted of two 10-μm sections (Leica RM 2235 rotary microtome). FFPE samples prepared with mutant tumor cells are considered KRAS positive, while those containing wild-type tumor cells are KRAS negative. Our KRAS PT panel (n = 10) consisted of eight mutant samples and two wild-type samples.
Evaluation of FFPE samples
The FFPE samples were evaluated by two reference laboratories (NCCL and National Institute for Food and Drug Control) before distribution. NCCL used Sanger sequencing and the National Institute for Food and Drug Control used matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry (MALDI-TOF-MS).
DNA was isolated with the QIAamp DNA FFPE Tissue Kit (QIA-GEN) according to manufacturer instructions and quantified by an absorbance-based nucleic acid quantification method (BioPhotometer, Eppendorf). Codons 12, 13, and 61 were PCR-amplified with two primer pairs; the products were purified and labeled with the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and sequenced on an ABI 3500DX Genetic Analyzer (Applied Biosystems). Both forward and reverse sequencing reactions were performed.
Isolated DNA was subjected to PCR amplification and primer extension with LungCarta Panel reagents (Sequenom, San Diego, CA, USA). The extension products were dispensed onto a SpectroCHIP array and detected by MassARRAY MALDI-TOF-MS. MassARRAY TYPER 4.0.43 software was used to analyze the results and identify the mutation and determine the percentage of mutant KRAS alleles for each sample.
Participants and data analysis
Participation was open to all laboratories in mainland China in 2013. All laboratories were assigned the same coded samples and required to use their routine procedures. Detailed instructions for storage conditions, DNA concentration range, and assay procedures were provided. Questionnaires were also sent to obtain information regarding the procedures employed, including the methods and reagents used for DNA extraction and mutation analysis, the concentration of extracted DNA, and typing results. The laboratories were also required to list the mutations that could be detected using their assays. Laboratories were asked to submit their results online within 2 weeks of specimen receipt.
The reported results were compared to the reference and four error types were used to evaluate the results [19] (Table 1) : mutation instead of wild-type (false-positive) or wild-type instead of mutation (false-negative); more than one mutation found, of which one is correct (false-positive); mutation found, but wrong mutation (false-positive); and mutation detection failure. Although the implications for patients differ, all mistakes were considered equally significant and thus unacceptable. Results that differed from the reference results were considered false-negative or -positive.
Results
Sample validation
Samples were verified by two reference laboratories. For each sample, the reference laboratories were required to assess three replicates that contained two sections each from the ends and middle of the FFPE blocks. Genomic DNA yields were > 200 ng per sample, which was adequate for KRAS mutation analysis. Table 1 summarizes the results of the verification. The methods used by the reference laboratories gave concordant results. The percentage of mutant KRAS alleles was > 50% in all samples.
Panel distribution and response
Sixty-three laboratories reported results before the closing date, including 41 clinical/hospital laboratories and 22 commercial laboratories and reagent manufacturers. A range of commercial nucleic acid extraction kits were used ( Figure 1A) Figure 1B and C) ; however, it is worth noting that 22.7% and 4.5% of the commercial laboratories applied MALDI-TOF-MS and PCR-Luminex, neither of which were used in clinical laboratories.
identified the G13D, G12A, and G12D mutations. In total, 69 errors were reported; 39.1% of these reported more than one mutation, of which one was correct. There were frequent instances of laboratories reporting the wrong mutation (27.5%) or reporting mutation in wild-type samples or no mutation in mutant samples (26.1%). Only 7.2% of the errors were caused by detection failure.
Proficiencies in KRAS mutation detection are shown in Table 2 . Only 55.6% of respondents correctly identified all the mutations. The best results (correct identification of all mutations) were provided by laboratories using Sanger sequencing (73.7%), pyrosequencing (80%), and MALDI-TOF-MS (80%). In contrast, only 39.2% of laboratories using ARMS and 25% of laboratories using HRM generated 100% proficient results.
The majority of errors were false-positive or -negative results. Fifteen false-negative results [15/504, (3.0%)] were reported. All mutations were detected by more than 90% of the laboratories with or without false-positive results, with the exception of KRAS-06, which carries the G12S mutation [53/63, (84.1%)]. Twenty-one of the laboratories reported 45 false-positive results including 52 falsepositive mutations; of these, 16 laboratories reported false-positive results in more than one sample ( Table 1) . Twelve of 14 laboratories using the commercial AmoyDx test reported false-positives (Table 3) . False-positives were reported by laboratories using ARMS-AmoyDx, in-house Sanger sequencing [10] , and pyrosequencing [3] . In-house and commercial ARMS assays, which were performed by only one or a few laboratories, yielded no false-positive results. 14 100% proficient: all mutations detected correctly. 80%-99% proficient: 80%-99% of mutations detected correctly. < 80% proficient: 60%-80% of mutations detected correctly. Not proficient: < 60% of mutations detected correctly.
KRAS testing performance
Wide-type samples KRAS-04 and KRAS-10 were most often correctly identified (95.2% and 98.4%, respectively) ( Table 1 ). More than 90% of laboratories correctly
Discussion
Artificial FFPE samples were created from cultured cell lines to construct a proficiency panel containing seven common KRAS mutations in codons 12 and 13. Dijkstra et al. prepared samples with 0%, 2.5%, 5%, 10%, and 15% mutated cells and assessed the reliability of a series of commonly used methods [13] . However, our study aimed primarily to evaluate KRAS genotyping; thus, only mutated cells were used and all the percentages of mutant KRAS alleles were determined to be > 50% by MALDI-TOF-MS. For DNA sequencing, the percentage of mutant KRAS alleles should be at least 10%-15% [16] . In this context, we concluded that the KRAS mutation abundance in PT samples should be higher than the detection limits for all methods.
The PT results suggest that only 55.6% of laboratories are capable of correctly identifying all KRAS mutations. Under normal conditions, false-negative results may occur due to low sensitivity for the chosen analytical method. In this study, a few false-negative results (3.0%) were reported for specimens with the percentage of mutant KRAS alleles > 50%; these results were generated by ARMS, Sanger sequencing, pyrosequencing, MALDI-TOF-MS, HRM, and PNA methods, indicating that method sensitivity might significantly differ between laboratories. KRAS mutations can be missed even by the most sensitive methods if the procedures are not performed correctly.
Surprisingly, there were a large number of falsepositive results, with only 42 of 63 data sets being 100% specific. The false-positive rate was higher than reported in the EQAs conducted in Europe [18] , Italy [23] , and the UK [14] . The proficiency panel contained only two KRAS mutation-negative samples; however, each KRAS-mutated sample could be regarded as the negative control for other mutations. Although some false-positive results might not change the clinical consequence, all false-positive results were scored as failures in this study. Usually, false-positive results are related to the assay (e.g., cross-reactivity) and laboratory conditions (e.g., contamination). In this study, systematic false positivity was found for the G12C sample; seven laboratories also detected G12R in this sample. Six laboratories detected G12C and nine detected G12V for the G12R sample. Indeed, 6/7 of the G12C results for G12R, 8/9 of the G12V results for G12C, and all of the G12R results for G12C were generated by the AmoyDx assay. This could be related to the crossreactivity patterns described in the AmoyDx kit manual. These laboratories may have problems distinguishing between the true mutation and cross-reactivity according to the algorithm illustrated in kit manual. It is also important to rule out contamination in the proficiency panel. KRAS-02 and KRAS-03 were detected correctly by 82.5% and 71.4% of laboratories using sensitive methods such as commercial ARMS assays, PCR-Luminex, MALDI-TOF-MS, and PNA. Indeed, several of these laboratories used the same assays used by laboratories reporting false-positive results, suggesting that proficiency panel contamination is unlikely.
Other false-positive results appeared to be randomly distributed and varied between laboratories, indicating that the problem was related to laboratory performance. For example, a laboratory using in-house pyrosequencing reported false-positive results in five samples, while the remaining four pyrosequencing laboratories detected all mutations correctly. Four laboratories reported the same false-positive results in more than one sample. False positivity can be caused by several factors. A very important factor is cross-contamination from PCR-amplified products and between samples during sample handling and DNA extraction. In China, regulations regarding the laboratory environment and operation procedures for laboratories performing PCR-based tests were established in 2002. However, some laboratories have adopted clinical KRAS testing only recently and have not adopted strict clinical standards. The inaccuracy of some in-house assays and operator errors are also possible causes of inaccurate results reporting. One laboratory using in-house Sanger sequencing generated different wrong mutation results for six KRAS-mutant samples. It is essential for laboratories to validate laboratory-developed KRAS mutation tests before using them. Methods for validating the performance characteristics of KRAS mutation assays, such as analytical specificity, sensitivity, and accuracy, have been described elsewhere [16] .
In conclusion, we performed the first nationwide KRAS PT in China to evaluate the detection capabilities of clinical laboratories. The study found that differences in performance were much larger between laboratories than between different types of assays. False-positive results are noteworthy in routine testing and laboratories should use enough negative controls to identify contamination from PCR products. In addition, validation of in-house assays is very important. Indeed, the samples in our panel represented an almost ideal sample setting. Nevertheless, many laboratories yielded poor test performance on these samples. Our findings show that KRAS testing must be standardized and that PT is essential. In our PT for KRAS testing, detailed data analysis for the PT results was provided so that all the participants were aware about the performance of various KRAS test methods and laboratories. We also provided the opportunity to retest samples if laboratories wished to analyze their results. In the future, PT for KRAS mutation testing will be performed twice a year and natural colorectal cancer tissue may be used in the test panel.
